Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Obesity Surgery
Published in: Obesity Surgery 11/2014

01-11-2014 | Original Contributions

Medication Cost is Significantly Reduced After Roux-en-Y Gastric Bypass in Obese Patients

Authors: Ina Gesquiere, Judith Aron-Wisnewsky, Veerle Foulon, Steeve Haggege, Bart Van der Schueren, Patrick Augustijns, Jean-Luc Bouillot, Karine Clement, Arnaud Basdevant, Jean-Michel Oppert, Marion Buyse

Published in: Obesity Surgery | Issue 11/2014

Login to get access

Abstract

Background

This study aims to determine the influence of Roux-en-Y gastric bypass (RYGB) on medication-related costs.

Methods

The study analyzed the types, dosages, and costs of drugs and medical devices prescribed before and after surgery (1, 3, 6, and 12 months and yearly thereafter) in patients who underwent RYGB between June 2004 and May 2010 and had an outpatient visit between December 2009 and May 2010 at Pitié-Salpêtrière University Hospital, Paris, France.

Results

The cohort included 143 patients (78 % female; mean age, 42.9 years; mean BMI, 48.6 kg/m2). Total prescription costs were significantly lower (−32 %, p < 0.001) 1 year after RYGB compared with preoperative costs. However, the cost for medications to prevent RYGB side effects (in particular nutritional deficiencies) displayed a 36-fold increase in the first month postsurgery, but then decreased progressively over time. Importantly, the cost related to the treatment of the two most frequent obesity-related diseases significantly decreased 1 year after surgery. Indeed, prescription costs for treatment of type 2 diabetes (T2D) and obstructive sleep apnea (OSA) (namely CPAP therapy considered as the gold standard treatment) were reduced 1 year after surgery by 85 and by 63 % (both p < 0.001), respectively. We also observed a trend toward a decrease in the prescription costs of other obesity-related diseases, although it did not reach significance in our cohort.

Conclusions

Considering medication to treat both obesity-related diseases and prevention of secondary effects of bariatric surgery, we observed that overall postoperative medication costs were significantly reduced one year after surgery, especially for T2D and OSA.
Literature
1.
WHO. Obesity and overweight. 2012. Fact Sheet No.311. Accessed June 10, 2013.
2.
Buchwald H, Avidor Y, Braunwald E, et al. Bariatric surgery: a systematic review and meta-analysis. JAMA. 2004;292(14):1724–37.CrossRefPubMed
3.
Narbro K, Agren G, Jonsson E, et al. Pharmaceutical costs in obese individuals: comparison with a randomly selected population sample and long-term changes after conventional and surgical treatment: the SOS intervention study. Arch Intern Med. 2002;162(18):2061–9.CrossRefPubMed
4.
Dyson PA. The therapeutics of lifestyle management on obesity. Diabetes Obes Metab. 2010;12(11):941–6.CrossRefPubMed
5.
Sjostrom L, Peltonen M, Jacobson P, et al. Bariatric surgery and long-term cardiovascular events. JAMA. 2012;307(1):56–65.CrossRefPubMed
6.
Bult MJ, van Dalen T, Muller AF. Surgical treatment of obesity. Eur J Endocrinol. 2008;158(2):135–45.CrossRefPubMed
7.
Dixon JB, Straznicky NE, Lambert EA, et al. Surgical approaches to the treatment of obesity. Nat Rev Gastroenterol Hepatol. 2011;8(8):429–37.CrossRefPubMed
8.
Suter M, Donadini A, Romy S, et al. Laparoscopic Roux-en-Y gastric bypass: significant long-term weight loss, improvement of obesity-related comorbidities and quality of life. Ann Surg. 2011;254(2):267–73.CrossRefPubMed
9.
de Aquino LA, Pereira SE, de Souza SJ, et al. Bariatric surgery: impact on body composition after Roux-en-Y gastric bypass. Obes Surg. 2012;22(2):195–200.CrossRefPubMed
10.
Vest AR, Heneghan HM, Agarwal S, et al. Bariatric surgery and cardiovascular outcomes: a systematic review. Heart. 2012;98(24):1763–77.CrossRefPubMed
11.
Cremieux PY, Ledoux S, Clerici C, et al. The impact of bariatric surgery on comorbidities and medication use among obese patients. Obes Surg. 2010;20(7):861–70.CrossRefPubMed
12.
Segal JB, Clark JM, Shore AD, et al. Prompt reduction in use of medications for comorbid conditions after bariatric surgery. Obes Surg. 2009;19(12):1646–56.CrossRefPubMed
13.
Neovius M, Narbro K, Keating C, et al. Health care use during 20 years following bariatric surgery. JAMA. 2012;308(11):1132–41.CrossRefPubMed
14.
Quesada BM, Kohan G, Roff HE, et al. Management of gallstones and gallbladder disease in patients undergoing gastric bypass. World J Gastroenterol. 2010;16(17):2075–9.CrossRefPubMedCentralPubMed
15.
16.
Sugerman HJ, Brewer WH, Shiffman ML, et al. A multicenter, placebo-controlled, randomized, double-blind, prospective trial of prophylactic ursodiol for the prevention of gallstone formation following gastric-bypass-induced rapid weight loss. Am J Surg. 1995;169(1):91–6.CrossRefPubMed
17.
Gasteyger C, Suter M, Gaillard RC, et al. Nutritional deficiencies after Roux-en-Y gastric bypass for morbid obesity often cannot be prevented by standard multivitamin supplementation. Am J Clin Nutr. 2008;87(5):1128–33.PubMed
18.
Poitou BC, Ciangura C, Coupaye M, et al. Nutritional deficiency after gastric bypass: diagnosis, prevention and treatment. Diabetes Metab. 2007;33(1):13–24.CrossRef
19.
Gastrointestinal surgery for severe obesity: National Institutes of Health Consensus Development Conference Statement. Am J Clin Nutr. 1992; 55 (2 Suppl): 615S-619S.
20.
Rossi VA, Winter B, Rahman NM, et al. The effects of Provent on moderate to severe obstructive sleep apnoea during continuous positive airway pressure therapy withdrawal: a randomised controlled trial. Thorax. 2013;68(9):854–9.CrossRefPubMed
21.
Makary MA, Clark JM, Shore AD, et al. Medication utilization and annual health care costs in patients with type 2 diabetes mellitus before and after bariatric surgery. Arch Surg. 2010;145(8):726–31.CrossRefPubMed
22.
Schauer PR, Burguera B, Ikramuddin S, et al. Effect of laparoscopic Roux-en Y gastric bypass on type 2 diabetes mellitus. Ann Surg. 2003;238(4):467–84.PubMedCentralPubMed
23.
Buchwald H, Estok R, Fahrbach K, et al. Weight and type 2 diabetes after bariatric surgery: systematic review and meta-analysis. Am J Med. 2009;122(3):248–56.CrossRefPubMed
24.
Pournaras DJ, Aasheim ET, Sovik TT, et al. Effect of the definition of type II diabetes remission in the evaluation of bariatric surgery for metabolic disorders. Br J Surg. 2012;99(1):100–3.CrossRefPubMed
25.
Schauer PR, Kashyap SR, Wolski K, et al. Bariatric surgery versus intensive medical therapy in obese patients with diabetes. N Engl J Med. 2012;366(17):1567–76.CrossRefPubMedCentralPubMed
26.
Carlsson LM, Peltonen M, Ahlin S, et al. Bariatric surgery and prevention of type 2 diabetes in Swedish obese subjects. N Engl J Med. 2012;367(8):695–704.CrossRefPubMed
27.
Wickremesekera K, Miller G, Naotunne TD, et al. Loss of insulin resistance after Roux-en-Y gastric bypass surgery: a time course study. Obes Surg. 2005;15(4):474–81.CrossRefPubMed
28.
Dirksen C, Jorgensen NB, Bojsen-Moller KN, et al. Mechanisms of improved glycaemic control after Roux-en-Y gastric bypass. Diabetologia. 2012;55:1890–901.CrossRefPubMed
29.
Thaler JP, Cummings DE. Minireview: hormonal and metabolic mechanisms of diabetes remission after gastrointestinal surgery. Endocrinology. 2009;150(6):2518–25.CrossRefPubMed
30.
Rubino F, Gagner M, Gentileschi P, et al. The early effect of the Roux-en-Y gastric bypass on hormones involved in body weight regulation and glucose metabolism. Ann Surg. 2004;240(2):236–42.CrossRefPubMedCentralPubMed
31.
Varela JE, Hinojosa MW, Nguyen NT. Resolution of obstructive sleep apnea after laparoscopic gastric bypass. Obes Surg. 2007;17(10):1279–82.CrossRefPubMed
32.
Grunstein RR, Stenlof K, Hedner JA, et al. Two year reduction in sleep apnea symptoms and associated diabetes incidence after weight loss in severe obesity. Sleep. 2007;30(6):703–10.PubMedCentralPubMed
33.
Rasheid S, Banasiak M, Gallagher SF, et al. Gastric bypass is an effective treatment for obstructive sleep apnea in patients with clinically significant obesity. Obes Surg. 2003;13(1):58–61.CrossRefPubMed
34.
Haines KL, Nelson LG, Gonzalez R, et al. Objective evidence that bariatric surgery improves obesity-related obstructive sleep apnea. Surgery. 2007;141(3):354–8.CrossRefPubMed
35.
Dixon JB, Schachter LM, O'Brien PE, et al. Surgical vs conventional therapy for weight loss treatment of obstructive sleep apnea: a randomized controlled trial. JAMA. 2012;308(11):1142–9.CrossRefPubMed
36.
Ashrafian H, le Roux CW, Rowland SP, et al. Metabolic surgery and obstructive sleep apnoea: the protective effects of bariatric procedures. Thorax. 2012;67(5):442–9.CrossRefPubMed
37.
Sjostrom L, Narbro K, Sjostrom CD, et al. Effects of bariatric surgery on mortality in Swedish obese subjects. N Engl J Med. 2007;357(8):741–52.CrossRefPubMed
38.
Adams TD, Gress RE, Smith SC, et al. Long-term mortality after gastric bypass surgery. N Engl J Med. 2007;357(8):753–61.CrossRefPubMed
39.
Heneghan HM, Meron-Eldar S, Brethauer SA, et al. Effect of bariatric surgery on cardiovascular risk profile. Am J Cardiol. 2011;108(10):1499–507.CrossRefPubMed
40.
Athyros VG, Tziomalos K, Karagiannis A, et al. Cardiovascular benefits of bariatric surgery in morbidly obese patients. Obes Rev. 2011;12(7):515–24.CrossRefPubMed
41.
Cunningham JL, Merrell CC, Sarr M, et al. Investigation of antidepressant medication usage after bariatric surgery. Obes Surg. 2012;22(4):530–5.CrossRefPubMed
42.
Julia C, Ciangura C, Capuron L, et al. Quality of life after Roux-en-Y gastric bypass and changes in body mass index and obesity-related comorbidities. Diabetes Metab. 2013;39(2):148–54.CrossRefPubMed
43.
Weiner JP, Goodwin SM, Chang HY, et al. Impact of bariatric surgery on health care costs of obese persons: a 6-year follow-up of surgical and comparison cohorts using health plan data. JAMA Surg. 2013;148(6):555–62.CrossRefPubMed
Metadata
Title
Medication Cost is Significantly Reduced After Roux-en-Y Gastric Bypass in Obese Patients
Authors
Ina Gesquiere
Judith Aron-Wisnewsky
Veerle Foulon
Steeve Haggege
Bart Van der Schueren
Patrick Augustijns
Jean-Luc Bouillot
Karine Clement
Arnaud Basdevant
Jean-Michel Oppert
Marion Buyse
Publication date
01-11-2014
Publisher
Springer US
Published in
Obesity Surgery / Issue 11/2014
Print ISSN: 0960-8923
Electronic ISSN: 1708-0428
DOI
https://doi.org/10.1007/s11695-014-1325-8

Other articles of this Issue 11/2014

Obesity Surgery 11/2014 Go to the issue

Original Contributions

Changes in Nutrients and Food Groups Intake Following Laparoscopic Roux-en-Y Gastric Bypass (RYGB)

Video Submission

Endoloop-Assisted Alignment—a Simple, Effective, Cheap, and Safe Technique to Aid Specimen Extraction Following Sleeve Gastrectomy

Original Contributions

Dietary Iodine Absorption is not Influenced by Malabsorptive Bariatric Surgery

Original Contributions

Long-Term Effects of Laparoscopic Roux-en-Y Gastric Bypass on Diabetes Mellitus, Hypertension and Dyslipidaemia in Morbidly Obese Patients

Original Contributions

Asymptomatic Gastric Bacterial Overgrowth After Bariatric Surgery: Are Long-Term Metabolic Consequences Possible?

Original Contributions

Subcutaneous Placement of Lap Band Port Without Fascial Fixation Provides Safe and Durable Access